Literature DB >> 2616245

Effects of acute viral respiratory tract infections in patients with cystic fibrosis.

N L Hordvik1, P König, B Hamory, M Cooperstock, C Kreutz, D Gayer, G Barbero.   

Abstract

To determine the effects of acute viral respiratory infections (ARI) in cystic fibrosis (CF) we studied all episodes of ARI in ten patients over a 2 year period. A daily diary card was kept on which they recorded all illnesses, including specific upper and lower respiratory symptoms, antibiotic use, and daily peak flow measurements. Recording of concurrent similar illnesses in other household members aided in confirming the onset of ARI, as did a home viral culturing technique and serial serum antibody levels against specific viral types. A total of 80% of the 35 recorded onsets of ARI (1.75/yr/subject) were confirmed by one or more of these methods. Five subjects with moderate to severe pulmonary function scores at the outset of the study had significantly greater decreases in PEFR during ARI episodes (42.4%) than those with milder disease (15.4%), and it took them significantly longer to recover to their baseline measurements (22 days vs. 15 days respectively). The majority of hospital admissions for pulmonary exacerbations were preceded by viral infections (7/8).

Entities:  

Mesh:

Year:  1989        PMID: 2616245     DOI: 10.1002/ppul.1950070406

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  11 in total

Review 1.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

2.  Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis.

Authors:  U B Schaad; U Bühlmann; R Burger; A Ruedeberg; A Wilder-Smith; M Rutishauser; F Sennhauser; C Herzog; M Zellmeyer; R Glück
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 3.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Ten years of viral and non-bacterial serology in adults with cystic fibrosis.

Authors:  I J Clifton; J A Kastelik; D G Peckham; A Hale; M Denton; C Etherington; S P Conway
Journal:  Epidemiol Infect       Date:  2007-03-12       Impact factor: 2.451

5.  Effects of upper respiratory tract infections in patients with cystic fibrosis.

Authors:  J Collinson; K G Nicholson; E Cancio; J Ashman; D C Ireland; V Hammersley; J Kent; C O'Callaghan
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

6.  A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.

Authors:  Christopher D Sibley; Michael D Parkins; Harvey R Rabin; Kangmin Duan; Jens C Norgaard; Michael G Surette
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

7.  Lung function from infancy to school age in cystic fibrosis.

Authors:  C S Beardsmore
Journal:  Arch Dis Child       Date:  1995-12       Impact factor: 3.791

Review 8.  Respiratory Viral Infections in Chronic Lung Diseases.

Authors:  Clemente J Britto; Virginia Brady; Seiwon Lee; Charles S Dela Cruz
Journal:  Clin Chest Med       Date:  2016-12-24       Impact factor: 2.878

Review 9.  Role of epithelial nitric oxide in airway viral infection.

Authors:  Weiling Xu; Shuo Zheng; Raed A Dweik; Serpil C Erzurum
Journal:  Free Radic Biol Med       Date:  2006-02-20       Impact factor: 7.376

Review 10.  Viral respiratory infections in cystic fibrosis.

Authors:  Bart E van Ewijk; Marieke M van der Zalm; Tom F W Wolfs; Cornelis K van der Ent
Journal:  J Cyst Fibros       Date:  2005-08       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.